Celldex Therapeutics Announces Completion of $345 Million Public Offering
On April 6, 2026, Celldex Therapeutics Inc. (Nasdaq: CLDX) confirmed the closure of an underwritten public offering that raised approximately $345 million in gross proceeds. The transaction involved the sale of 11,896,750 newly issued shares at a price of $29.00 per share, accompanied by the full exercise of the underwriters’ option for an additional 1,551,750 shares.
Key Details of the Offering
| Item | Information |
|---|---|
| Total Shares Issued | 11,896,750 (new) + 1,551,750 (option) |
| Public Offering Price | $29.00 per share |
| Gross Proceeds | ≈ $345 million |
| Underwriters | Leerink Partners, TD Cowen, Guggenheim Securities, Cantor (joint bookrunners); LifeSci Capital and H.C. Wainwright & Co. (co‑lead managers) |
| Registration Basis | Shelf registration statement on Form S‑3 (File No. 333‑275300) |
| Effective Date of Registration | November 3, 2023 |
| Exclusions | Underwriting discounts, commissions, and other offering‑related expenses are not included in the gross proceeds figure. |
Market Context
The offering followed a series of equity financing steps announced earlier in April 2026, when the company priced a similar underwritten public offering of 10,345,000 shares at the same $29.00 price point. The additional shares purchased by the underwriters—amounting to roughly 13 % of the total shares sold—represent a fully exercised option that was previously signaled by the company.
Despite the infusion of capital, the stock experienced a modest decline of 0.64 % upon announcement, a pattern consistent with recent equity offerings by Celldex and other biotech peers. Analysts noted that this slight negative reaction reflects a standard dilution overhang rather than a sector‑wide movement, as contemporaneous biotech stocks (e.g., COGT, AUPH, VERA, ARDX) recorded gains between 0.9 % and 4.1 %.
Implications for Celldex’s Pipeline
Celldex Therapeutics, a biopharmaceutical company listed on Nasdaq, focuses on immunological applications across a broad spectrum of diseases—including autoimmune disorders, cardiovascular conditions, cancer, inflammation, infectious diseases, and organ transplant rejection. The newly raised capital is earmarked to advance clinical and commercial milestones within this diversified pipeline, potentially accelerating the development of its next‑generation therapeutics.
Current Shareholder Landscape
The issuance of 11,896,750 new shares expands the company’s equity base, thereby increasing shareholder dilution risk. However, the substantial cash infusion—coupled with the company’s market cap of $2.07 billion—positions Celldex to navigate the competitive biotech landscape more robustly.
Closing Remarks
The successful completion of this $345 million offering marks a significant milestone in Celldex Therapeutics’ capital‑raising trajectory. Investors will be watching closely to see how the additional resources are deployed to support the company’s therapeutic agenda and to assess the long‑term impact on shareholder value.
